Expanding Horizons: Antibody Drug Conjugates in Non-Small Cell Lung Cancer

home / insights / expanding-horizons-antibody-drug-conjugates-in-non-small-cell-lung-cancer

Martin Dietrich, MD, PhD, and Wade Thomas Iams, MD, discuss the role of antibody-drug conjugates (ADCs) in non-small cell lung cancer (NSCLC) and review the various biomarkers for targeted therapy.

Overview of Antibody Drug Conjugates in Lung Cancer

EP. 1: Overview of Antibody Drug Conjugates in Lung Cancer

Martin Dietrich, MD, PhD;Wade Thomas Iams, MD
June 2nd 2023

Wade Thomas Iams, MD, provides an overview of antibody drug conjugates in the treatment of patients with lung cancer, including challenges and impact on clinical practice.

ADCs in Development for the Treatment of Lung Cancer

EP. 2: ADCs in Development for the Treatment of Lung Cancer

Martin Dietrich, MD, PhD;Wade Thomas Iams, MD
June 2nd 2023

Drs Martin Dietrich and Wade Thomas Iams discuss the differences between the targets, payloads, and linker technologies of the antibody drug conjugates in development for lung cancer.

Targeting CEACAM5 in Patients with Non-Small Cell Lung Cancer

EP. 3: Targeting CEACAM5 in Patients with Non-Small Cell Lung Cancer

Martin Dietrich, MD, PhD;Wade Thomas Iams, MD
June 9th 2023

Martin Dietrich, MD, PhD, details the molecular target CEACAM5 and its use in the treatment of patients with non-small cell lung cancer.

HER2-Directed Agents in NSCLC

EP. 4: HER2-Directed Agents in NSCLC

Martin Dietrich, MD, PhD;Wade Thomas Iams, MD
June 9th 2023

Dr Wade Thomas Iams explains how trastuzumab deruxtecan became the standard-of-care for HER2-mutated non-small cell lung cancer.

Targeting HER3 in EGFR-Mutant NSCLC

EP. 5: Targeting HER3 in EGFR-Mutant NSCLC

Martin Dietrich, MD, PhD;Wade Thomas Iams, MD
June 16th 2023

Experts review data on treatment with HER3-directed agents in NSCLC for patients with EGFR mutations.

Exploring TROP2 Expression in Patients with NSCLC

EP. 6: Exploring TROP2 Expression in Patients with NSCLC

Martin Dietrich, MD, PhD;Wade Thomas Iams, MD
June 16th 2023

Martin Dietrich, MD, PhD, and Wade Thomas Iams, MD, review the value of TROP2 as a target in patients with NSCLC.